---
document_datetime: 2025-12-29 09:23:41
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vazkepa.html
document_name: vazkepa.html
version: success
processing_time: 0.3317423
conversion_datetime: 2025-12-30 01:52:32.924204
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Vazkepa

[RSS](/en/individual-human-medicine.xml/67429)

##### Authorised

This medicine is authorised for use in the European Union

icosapent ethyl Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Vazkepa](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Vazkepa is a medicine for reducing the risk of cardiovascular events such as heart attack, stroke and other problems caused by blocked blood circulation. It is for use as add-on treatment in adults being treated with a statin medicine who have high levels of triglycerides (a type of fat) in their blood.

Vazkepa is to be used in patients either with a cardiovascular disease (a condition that affects the heart or circulation) or with diabetes and another condition that increases the risk of cardiovascular events.

Vazkepa contains the active substance icosapent ethyl.

Expand section

Collapse section

## How is Vazkepa used?

Vazkepa can only be obtained with a prescription. It is available as capsules, each containing 998 mg of icosapent ethyl.

The recommended dose is two capsules twice daily, with or after a meal.

For more information about using Vazkepa, see the package leaflet or contact your doctor or pharmacist.

## How does Vazkepa work?

It is not clear exactly how icosapent ethyl, the active substance in Vazkepa works, but it is likely to have an anti-inflammatory effect, reduce levels of harmful triglyceride-rich proteins and have protective antioxidant effect. As a result, the medicine is likely to reduce the build-up of fatty deposits in blood vessels and so prevent them becoming blocked.

## What benefits of Vazkepa have been shown in studies?

A study involving over 8,000 patients, who either had cardiovascular disease or were at high risk of it, found Vazkepa effective at reducing cardiovascular events. Such events included heart attack, stroke, blockages or interruption in blood supply to the heart muscle, and death from cardiovascular events. All patients in the study had raised triglyceride levels and were being treated with a statin. Cardiovascular events occurred in 17% (705 out of 4,089) of patients taking Vazkepa compared with 22% (901 out of 4,090) of patients who received placebo (a dummy treatment).

## What are the risks associated with Vazkepa?

The most common side effects with Vazkepa (which may affect up to 1 in 10 people) are bleeding, peripheral oedema (swelling in the feet and arms because of fluid build-up), atrial fibrillation (when the upper chambers of the heart do not pump blood effectively), constipation, bone and muscle pain, gout and rash.

Patients must not take Vazkepa if they are allergic to soya or to any of the ingredients of the medicine.

For the full list of side effects and restrictions of Vazkepa, see the package leaflet.

## Why is Vazkepa authorised in the EU?

Vazkepa was found effective at reducing cardiovascular events in patients at high risk of such events, who were taking a statin and had high levels of triglycerides. The side effects of Vazkepa were considered manageable.

The European Medicines Agency therefore decided that Vazkepa's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Vazkepa?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vazkepa have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Vazkepa are continuously monitored. Side effects reported with Vazkepa are carefully evaluated and any necessary action taken to protect patients.

## Other information about Vazkepa

Vazkepa received a marketing authorisation valid throughout the EU on 26 March 2021.

Vazkepa : EPAR - Medicine overview

Reference Number: EMA/68608/2021

English (EN) (135.97 KB - PDF)

**First published:** 14/04/2021

[View](/en/documents/overview/vazkepa-epar-medicine-overview_en.pdf)

[Other languages (21)](#file-language-dropdown-257)

български (BG) (158.95 KB - PDF)

**First published:**

14/04/2021

[View](/bg/documents/overview/vazkepa-epar-medicine-overview_bg.pdf)

español (ES) (135.42 KB - PDF)

**First published:**

14/04/2021

[View](/es/documents/overview/vazkepa-epar-medicine-overview_es.pdf)

čeština (CS) (158.31 KB - PDF)

**First published:**

14/04/2021

[View](/cs/documents/overview/vazkepa-epar-medicine-overview_cs.pdf)

Deutsch (DE) (138.8 KB - PDF)

**First published:**

14/04/2021

[View](/de/documents/overview/vazkepa-epar-medicine-overview_de.pdf)

eesti keel (ET) (123.69 KB - PDF)

**First published:**

14/04/2021

[View](/et/documents/overview/vazkepa-epar-medicine-overview_et.pdf)

ελληνικά (EL) (157.28 KB - PDF)

**First published:**

14/04/2021

[View](/el/documents/overview/vazkepa-epar-medicine-overview_el.pdf)

français (FR) (137.13 KB - PDF)

**First published:**

14/04/2021

[View](/fr/documents/overview/vazkepa-epar-medicine-overview_fr.pdf)

hrvatski (HR) (155.32 KB - PDF)

**First published:**

14/04/2021

[View](/hr/documents/overview/vazkepa-epar-medicine-overview_hr.pdf)

italiano (IT) (133.98 KB - PDF)

**First published:**

14/04/2021

[View](/it/documents/overview/vazkepa-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (163.88 KB - PDF)

**First published:**

14/04/2021

[View](/lv/documents/overview/vazkepa-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (157.12 KB - PDF)

**First published:**

14/04/2021

[View](/lt/documents/overview/vazkepa-epar-medicine-overview_lt.pdf)

magyar (HU) (154.43 KB - PDF)

**First published:**

14/04/2021

[View](/hu/documents/overview/vazkepa-epar-medicine-overview_hu.pdf)

Malti (MT) (159.36 KB - PDF)

**First published:**

14/04/2021

[View](/mt/documents/overview/vazkepa-epar-medicine-overview_mt.pdf)

Nederlands (NL) (135.04 KB - PDF)

**First published:**

14/04/2021

[View](/nl/documents/overview/vazkepa-epar-medicine-overview_nl.pdf)

polski (PL) (158.08 KB - PDF)

**First published:**

14/04/2021

[View](/pl/documents/overview/vazkepa-epar-medicine-overview_pl.pdf)

português (PT) (136.24 KB - PDF)

**First published:**

14/04/2021

[View](/pt/documents/overview/vazkepa-epar-medicine-overview_pt.pdf)

română (RO) (155.49 KB - PDF)

**First published:**

14/04/2021

[View](/ro/documents/overview/vazkepa-epar-medicine-overview_ro.pdf)

slovenčina (SK) (122.99 KB - PDF)

**First published:**

14/04/2021

[View](/sk/documents/overview/vazkepa-epar-medicine-overview_sk.pdf)

slovenščina (SL) (118.34 KB - PDF)

**First published:**

14/04/2021

[View](/sl/documents/overview/vazkepa-epar-medicine-overview_sl.pdf)

Suomi (FI) (133.51 KB - PDF)

**First published:**

14/04/2021

[View](/fi/documents/overview/vazkepa-epar-medicine-overview_fi.pdf)

svenska (SV) (105.25 KB - PDF)

**First published:**

14/04/2021

[View](/sv/documents/overview/vazkepa-epar-medicine-overview_sv.pdf)

Vazkepa : EPAR - Risk-management-plan summary

English (EN) (226.11 KB - PDF)

**First published:** 14/04/2021

[View](/en/documents/rmp-summary/vazkepa-epar-risk-management-plan-summary_en.pdf)

## Product information

Vazkepa : EPAR - Product information

English (EN) (241.77 KB - PDF)

**First published:** 14/04/2021

**Last updated:** 01/08/2024

[View](/en/documents/product-information/vazkepa-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-694)

български (BG) (413.71 KB - PDF)

**First published:**

01/08/2024

[View](/bg/documents/product-information/vazkepa-epar-product-information_bg.pdf)

español (ES) (273.04 KB - PDF)

**First published:**

01/08/2024

[View](/es/documents/product-information/vazkepa-epar-product-information_es.pdf)

čeština (CS) (381.17 KB - PDF)

**First published:**

01/08/2024

[View](/cs/documents/product-information/vazkepa-epar-product-information_cs.pdf)

dansk (DA) (274.03 KB - PDF)

**First published:**

01/08/2024

[View](/da/documents/product-information/vazkepa-epar-product-information_da.pdf)

Deutsch (DE) (294.7 KB - PDF)

**First published:**

01/08/2024

[View](/de/documents/product-information/vazkepa-epar-product-information_de.pdf)

eesti keel (ET) (275.46 KB - PDF)

**First published:**

01/08/2024

[View](/et/documents/product-information/vazkepa-epar-product-information_et.pdf)

ελληνικά (EL) (413.33 KB - PDF)

**First published:**

01/08/2024

[View](/el/documents/product-information/vazkepa-epar-product-information_el.pdf)

français (FR) (284.73 KB - PDF)

**First published:**

01/08/2024

[View](/fr/documents/product-information/vazkepa-epar-product-information_fr.pdf)

hrvatski (HR) (417.37 KB - PDF)

**First published:**

01/08/2024

[View](/hr/documents/product-information/vazkepa-epar-product-information_hr.pdf)

íslenska (IS) (255.6 KB - PDF)

**First published:**

01/08/2024

[View](/is/documents/product-information/vazkepa-epar-product-information_is.pdf)

italiano (IT) (301.7 KB - PDF)

**First published:**

01/08/2024

[View](/it/documents/product-information/vazkepa-epar-product-information_it.pdf)

latviešu valoda (LV) (382.58 KB - PDF)

**First published:**

01/08/2024

[View](/lv/documents/product-information/vazkepa-epar-product-information_lv.pdf)

lietuvių kalba (LT) (350.84 KB - PDF)

**First published:**

01/08/2024

[View](/lt/documents/product-information/vazkepa-epar-product-information_lt.pdf)

magyar (HU) (387.53 KB - PDF)

**First published:**

01/08/2024

[View](/hu/documents/product-information/vazkepa-epar-product-information_hu.pdf)

Malti (MT) (389.49 KB - PDF)

**First published:**

01/08/2024

[View](/mt/documents/product-information/vazkepa-epar-product-information_mt.pdf)

Nederlands (NL) (293.91 KB - PDF)

**First published:**

01/08/2024

[View](/nl/documents/product-information/vazkepa-epar-product-information_nl.pdf)

norsk (NO) (239.36 KB - PDF)

**First published:**

01/08/2024

[View](/no/documents/product-information/vazkepa-epar-product-information_no.pdf)

polski (PL) (377.26 KB - PDF)

**First published:**

01/08/2024

[View](/pl/documents/product-information/vazkepa-epar-product-information_pl.pdf)

português (PT) (249.71 KB - PDF)

**First published:**

01/08/2024

[View](/pt/documents/product-information/vazkepa-epar-product-information_pt.pdf)

română (RO) (376.46 KB - PDF)

**First published:**

01/08/2024

[View](/ro/documents/product-information/vazkepa-epar-product-information_ro.pdf)

slovenčina (SK) (355.46 KB - PDF)

**First published:**

01/08/2024

[View](/sk/documents/product-information/vazkepa-epar-product-information_sk.pdf)

slovenščina (SL) (402.98 KB - PDF)

**First published:**

01/08/2024

[View](/sl/documents/product-information/vazkepa-epar-product-information_sl.pdf)

Suomi (FI) (252.82 KB - PDF)

**First published:**

01/08/2024

[View](/fi/documents/product-information/vazkepa-epar-product-information_fi.pdf)

svenska (SV) (278.11 KB - PDF)

**First published:**

01/08/2024

[View](/sv/documents/product-information/vazkepa-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0024 31/07/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Vazkepa : EPAR - All authorised presentations

English (EN) (6.95 KB - PDF)

**First published:** 14/04/2021

**Last updated:** 25/01/2022

[View](/en/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-96)

български (BG) (31.08 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/bg/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_bg.pdf)

español (ES) (6.94 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/es/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_es.pdf)

čeština (CS) (30.67 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/cs/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (5.89 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/da/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (7.44 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/de/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (7.53 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/et/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (29.3 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/el/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_el.pdf)

français (FR) (7.37 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/fr/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (30.01 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/hr/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (6.17 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/is/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_is.pdf)

italiano (IT) (7.43 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/it/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (29.86 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/lv/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (28.57 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/lt/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (17.49 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/hu/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (30.97 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/mt/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (7.21 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/nl/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (5.7 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/no/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_no.pdf)

polski (PL) (33.67 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/pl/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_pl.pdf)

português (PT) (6.49 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/pt/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_pt.pdf)

română (RO) (75.72 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/ro/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (30.64 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/sk/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (15.13 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/sl/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (5.92 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/fi/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (5.97 KB - PDF)

**First published:**

14/04/2021

**Last updated:**

25/01/2022

[View](/sv/documents/all-authorised-presentations/vazkepa-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Vazkepa Active substance Icosapent ethyl International non-proprietary name (INN) or common name icosapent ethyl Therapeutic area (MeSH) Dyslipidemias Anatomical therapeutic chemical (ATC) code C10AX

### Pharmacotherapeutic group

Lipid modifying agents

### Therapeutic indication

Indicated to reduce cardiovascular risk as an adjunct to statin therapy.

## Authorisation details

EMA product number EMEA/H/C/005398

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Amarin Pharmaceuticals Ireland Limited

88 Harcourt Street

Opinion adopted 28/01/2021 Marketing authorisation issued 26/03/2021 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Vazkepa : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (130.59 KB - PDF)

**First published:** 07/07/2021

**Last updated:** 01/08/2024

[View](/en/documents/procedural-steps-after/vazkepa-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Vazkepa-H-C-PSUSA-00010922-202107 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

English (EN) (96.01 KB - PDF)

**First published:** 02/05/2022

[View](/en/documents/scientific-conclusion/vazkepa-h-c-psusa-00010922-202107-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Vazkepa : EPAR - Public assessment report

Adopted

Reference Number: EMA/145271/2021

English (EN) (4.99 MB - PDF)

**First published:** 14/04/2021

[View](/en/documents/assessment-report/vazkepa-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Vazkepa

Adopted

Reference Number: EMA/CHMP/646053/2020

English (EN) (184.45 KB - PDF)

**First published:** 01/02/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-vazkepa_en.pdf)

#### News on Vazkepa

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021) 29/01/2021

**This page was last updated on** 01/08/2024

## Share this page

[Back to top](#main-content)